New York, NY (PRWEB) August 16, 2014
A Risperdal (http://www.lawreward.com/risperdal/) meeting is scheduled to take place next month in the Philadelphia Court of Common Pleas, where hundreds of lawsuits over the antipsychotic medication are continuing to move forward, Bernstein Liebhard LLP reports.
According to a Calendar posted on the Court’s website, parties involved in the consolidated Pennsylvania litigation will convene on September 16th at 2:00 p.m. to discuss claims filed against Johnson & Johnson and its subsidiary, Janssen Pharmaceuticals, Inc. Items likely to be included on the meeting’s agenda will be cases that allege new-onset male breast development caused by the medication, a condition referred to as gynecomastia. Court documents in the proceeding reflect nearly 700 cases involving Risperdal now filed in the Philadelphia Court of Common Pleas, many of which claim the need for a mastectomy, liposuction and other surgical intervention to repair the male breast growth complications was allegedly caused by use of Risperdal. (In Re: Risperdal Litigation, Case Number 100300296)
“Our Firm is looking forward to the upcoming Risperdal meeting in Philadelphia, as we continue to represent clients who allegedly developed male breast growth complications due to the antipsychotic drug,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including Risperdal. The Firm is currently offering free and confidential case evaluations to individuals who may have been injured as a result of the medication.
Risperdal is an atypical antipsychotic medication approved to treat schizophrenia and bipolar disorder in adults and adolescents between the ages of 10 and 17. The drug is also cleared by the U.S. Food and Drug Administration (FDA) to treat irritability in children ages 5-to-16 years old with autistic disorder. According to research, Risperdal is also frequently prescribed off-label for symptoms associated with ADHD.
As Risperdal lawsuits alleging male gynecomastia continue to be filed in the Philadelphia Common Pleas, a report published this month lends evidence to the association between Risperdal and this particular complication. According to a study published on August 6th in the Journal of Clinical Psychopharmacology, 27 out of 174 men exposed to risperidone, the active ingredient in Risperdal, developed male breasts within 60 days. The research was led by scientists from the University of British Columbia and involved health records of more than 82,000 men from 2001 to 2011. The men were aged between 40 and 85 years old.*
According to Risperdal lawsuits filed in the Philadelphia Court of Common Pleas, Johnson & Johnson and Janssen failed to adequately warn men and their doctors about the risk for gynecomastia and other side effects. The companies have also been accused of marketing the drug for off-label uses.
In November 2013, Johnson & Johnson agreed to a $2.5 million settlement with the U.S. Department of Justice involving claims that Risperdal and several other medications were promoted for uses not approved by the FDA. In the case for Risperdal, this may involve promotion of the drug’s marketing in children before it was cleared for pediatric uses in 2006. The federal government also accused Johnson & Johnson and Janssen of withholding information about Risperdal’s side effects, which may include its association with gynecomastia.
Men and young boys who developed gynecomastia after taking Risperdal may be eligible to file a lawsuit seeking compensation for out-of-pocket medical expenses, lost wages, as well as any pain and suffering that may have resulted from use of the medication. Learn more about filing a Risperdal lawsuit by visiting Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.
*journals.lww.com/psychopharmacology/Citation/publishahead/Risperidone_Use_and_Risk_for_Gynecomastia_in_Men_.99394.aspx, Journal of Clinical Psycopharmacology
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
info (at) consumerinjurylawyers (dot) com
Read the full story at http://www.prweb.com/releases/risperdal-lawsuit/risperdal-gynecomastia/prweb12099622.htm.
Copyright©2014 Vocus, Inc.
All rights reserved